medigraphic.com
Colegio de Medicina Interna de México.

2010, Number 5

<< Back Next >>

Med Int Mex 2010; 26 (5)

National Survey on the Treatment, Metabolic and Cardiovascular Risk Factors Control in Type 2 Diabetes Patients treated by Specialists on Internal Medicine

Escobedo PJ, Reinoso RJ, Flores GL, Olvera GL, Heredia MP, Carranza MJ, Aguilar GJL, Villegas PLO, Vidales RJA, Ruiz LA, Paz BJA, Bernal EJE, Ruiz TJC, Domínguez LLE, Ramos BJL, Valentín GJMM, Jiménez JEA, Medina GOS, Nevares LA, Liceaga CMG, Castro MMG

Language: Spanish
References: 32
Page: 449-456
PDF size: 311.64 Kb.


ABSTRACT

Background: Coronary heart disease is the main cause of mortality in diabetes. Recent clinical trials show the benefit of controlling cardiovascular risk factors to diminish the occurrence of coronary heart disease. The objective of this study was to assess the degree of metabolic control among patients with diabetes treated by internists.
Material and methods: An online survey was conducted in the web page of the Mexican Collage of Internal Medicine (http://www.cmim. org/ent/index_OK.php). Once registered the fellow captured information on register patients, including socio-demographic data, antecedents and treatment oh hypertension, dyslipidemia and diabetes. Values of control parameters were entered and ADA criteria was used to consider control of them. Mann-.Whitney U and chi squared were used for statistical analysis.
Results: 1,495 patients were included in the study with a mean age of 60.7 yeasrs. The proportion of patients with values considered in control were for HbA1c ‹7% 40%, LDL-c ‹100 mg/dL 43.8%, HDL-c ›40 mg/dL 46.3%, triglycerides ‹150 mg/dL 39.8% and blood pressure ‹130/80 mmHg 51.3%. Men had a better control. Patients who were using three or more antihypertensive drugs had a better blood pressure control. Patients following a proper diet had a better control.
Conclusions: The control of the main cardiovascular risk factors is still unsatisfactory in Mexican patients with diabetes, although comparable to control achieved in other populations. There is a need to highlight the importance of better controlling type 2 diabetes patients by the internist



REFERENCES

  1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73-78.

  2. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;113:791-798.

  3. Dale AC, Vatten LJ, Nilsen TI, Midthjell K, Wiseth R. Seculardecline in mortality from coronary heart disease in adults with diabetes mellitus: cohort study. BMJ 2008;337:236.

  4. Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA 2004;292:2495-2499.

  5. Buse JB, Ginsberg HN, Barkis GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-172.

  6. Adler AI, Stratton IM, Neil AW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419.

  7. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-1576.

  8. Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes. Part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol 2007;49:631-642.

  9. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPICNorfolk). BMJ 2001;322:1-6.

  10. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Int Med 2004;141:421-431.

  11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

  12. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.

  13. The Action to Control Cardiovascular Risk in Diabetes Study G roup. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545-2559.

  14. Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW. 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.

  15. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 2007;30:S4-41.

  16. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.

  17. American Diabetes Association. Standards of Medical Care in Diabetes-2010. Diabetes Care 2010;33:S11-S61.

  18. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. A preliminary report. Diabetes Care 2004;27:17-20.

  19. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342.

  20. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-86.

  21. Selvin E, Coresh J, Golden SH, Boland LL, et al. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes. The Atherosclerosis Risk in Communities study. Diabetes Care 2005;28:1965-1973.

  22. Aguilar-Salinas CA, Velazquez Monroy O, Gómez-Pérez FJ, González Chávez A, Lara Esqueda A, Molina Cuevas V, Rull-Rodrigo JA, Tapia Conyer R, for the ENSA (Encuesta Nacional de Salud) 2000 Group. Diabetes Care 2003;26:2021-2026.

  23. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: Unites States, 1988-2002. Ann Intern Med 2006;144:465-474.

  24. Harris SB, Ekoé JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diab Res Clin Pract 2005;70:90-97.

  25. Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdóttir for the Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003. Diabet Med 2005;22:1420-1426. Medicina Interna de México Volumen 456 olumen 26, núm. 5, septiembre-octubre 2010 Escobedo de la Peña J y col.

  26. Imperatore G, Cadwell BL, Geiss L, et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes. National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol 2004;160:531-539.

  27. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ1998;316:823-828. 28. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008;118:576-585.

  28. Smith SC, Allen J, Blair SN, et al. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update. Circulation 2006; 113:2363-2372.

  29. Snow V, Aronson MD, Hombake ER, Mottur-Pilson C, Weiss KB, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Ann Intern Med 2004; 140:644-649.

  30. Costa J, Borges M, David C, Carneiro AV. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115-1124.

  31. Hu FB. The role of diet and lifestyle modifications in the statin era. J Am Diet Assoc 2005;105:1718-1721.

  32. Kirk JK, Passmore LV, Bell RA, et al. Disparities in A1c levels between Hispanic and non-Hispanic white adults with diabetes. A meta-analysis. Diabetes Care 2008;31:240-246.




2020     |     www.medigraphic.com